ROCO
4195
Market cap42mUSD
Jun 04, Last price
17.00TWD
Name
Genomics Bioscience & Technology Co Ltd
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Genomics BioSci & Tech. Co.,Ltd. specializes in providing a comprehensive array of services within the field of genomic sequencing. Its core offerings encompass standard and intricate DNA sequencing, including TAF-certified options, with clients also benefiting from complimentary sequencing primer and primer walking services. Beyond sequencing, the company is proficient in synthesizing peptides, genes, and oligonucleotides. Furthermore, its analytical capabilities extend to crucial laboratory services such as sample preparation, gene expression analysis, genotyping, DNA methylation analysis, and microbial identification. The firm also delivers advanced sequencing solutions, including genome-level, targeted, gene regulation, and metagenomic sequencing, alongside cutting-edge third-generation sequencing technologies. To support these services, it offers integrated sequencing platforms and streamlined workflows. Additionally, Genomics BioSci & Tech. Co.,Ltd. provides specialized diagnostic screenings, such as non-invasive prenatal testing (NIPT), spinal muscular atrophy (SMA) carrier screening, and fragile X syndrome premutation screening. Established in 2001, the company's headquarters are located in New Taipei City, Taiwan.
Key people
Mengxian Zhou
Chairman of the Board · since 2021
Zuo-wei Zhang
Chief Financial Officer, Corporate Governance Officer · since 2023
Shengda Xu
Chief Information Officer · since 2023
Junsheng Liu
Deputy General Manager-Proteome & Metabolism Business Group · since 2013
Weiqun Zhang
Deputy General Manager-Finance
Hanming Zhang
Deputy General Manager-Next Generation Sequencing Business Group · since 2013
Shufen Zhang
Head of Finance & Accounting · since 2022
Junqi Jiang
Chief Executive Officer, Chief Technology Officer, General Manager, Director · since 2023
Wanqi Li
Director · since 2021
Shijia Lin
Director · since 2022
Zuowei Zhang
Chief Operating Officer, Deputy General Manager-Life Technology Business Group, Director · since 2021
Yingting Zhao
Director · since 2018
Renhong Cheng
Independent Director · since 2023
Yu-Jen Hsiao
Independent Director · since 2021
Jei-Fu Shaw
Independent Director · since 2021
Valuation
Title TWD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | |
| Income | |||||||
Revenues | |||||||
Cost of revenue | |||||||
Unusual Expense (Income) | |||||||
NOPBT | |||||||
NOPBT Margin | |||||||
Operating Taxes | |||||||
Tax Rate | |||||||
NOPAT | |||||||
Net income | |||||||
Dividends | |||||||
Dividend yield | |||||||
Proceeds from repurchase of equity | |||||||
BB yield | |||||||
| Debt | |||||||
Debt current | |||||||
Long-term debt | |||||||
Deferred revenue | |||||||
Other long-term liabilities | |||||||
Net debt | |||||||
| Cash flow | |||||||
Cash from operating activities | |||||||
CAPEX | |||||||
Cash from investing activities | |||||||
Cash from financing activities | |||||||
FCF | |||||||
| Balance | |||||||
Cash | |||||||
Long term investments | |||||||
Excess cash | |||||||
Stockholders' equity | |||||||
Invested Capital | |||||||
ROIC | |||||||
ROCE | |||||||
| EV | |||||||
Common stock shares outstanding | |||||||
Price | |||||||
Market cap | |||||||
EV | |||||||
EBITDA | |||||||
EV/EBITDA | |||||||
Interest | |||||||
Interest/NOPBT | |||||||